Research graph
References from KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine. Local targets link to admitted publications; unresolved targets remain external evidence.
Targeting KRAS: from Metabolic Regulation to Cancer Treatment
10.1186/s12943-024-02216-3 · 2025 · External reference
Extracellular Signal‐Regulated Kinases: One Pathway, Multiple Fates
10.3390/cancers16010095 · 2023 · External reference
Targeting KRAS Mutant Non‐Small‐Cell Lung Cancer: Past, Present and Future
10.3390/ijms21124325 · 2020 · External reference
Resistance to KRAS G12C Inhibition in Non‐Small Cell Lung Cancer
10.1007/s11912-023-01436-y · 2023 · External reference
VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non‐Small Cell Lung Cancer
10.1177/15330338241264853 · 2024 · External reference
KRAS: a Druggable Target in Colon Cancer Patients
10.3390/ijms23084120 · 2022 · External reference
KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration
10.3390/jcm12020709 · 2023 · External reference
The Prevalence and Prognostic Significance of KRAS Mutation Subtypes in Lung Adenocarcinomas from Chinese Populations
10.2147/ott.s96834 · 2016 · External reference
The Prognosis and Adjuvant Chemotherapy in KRAS Mutation Patients with Stage I Lung Adenocarcinoma
10.1016/j.cson.2024.100069 · 2024 · External reference
Drugging KRAS: Current Perspectives and state‐of‐Art Review
10.1186/s13045-022-01375-4 · 2022 · External reference
KRAS Mutation: from Undruggable to Druggable in Cancer
10.1038/s41392-021-00780-4 · 2021 · External reference
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation with Immuno‐Oncology Biomarkers in KRAS‐Mutated Cancers
10.1200/po.21.00245 · 2022 · External reference
KRAS G12C Inhibitor Combination Therapies: Current Evidence and Challenge
10.3389/fonc.2024.1380584 · 2024 · External reference
Is KRAS (G12C) Inhibitor Monotherapy for Non‐Small Cell Lung Cancer Possible? A Review of Current Literature
10.1080/29947448.2024.2427647 · 2025 · External reference
RAS Signaling in Carcinogenesis, Cancer Therapy and Resistance Mechanisms
10.1186/s13045-024-01631-9 · 2024 · External reference
Sotorasib: First Approval
10.1007/s40265-021-01574-2 · 2021 · External reference
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
10.1007/s11523-024-01055-y · 2024 · External reference
Mechanisms of Resistance to KRASG12C Inhibitors
10.3390/cancers13010151 · 2021 · External reference
Prognostic and Therapeutic Impact of the KRAS G12C Mutation in Colorectal Cancer
10.3389/fonc.2023.1252516 · 2023 · External reference
KRAS G12C Mutation: from Undruggable Target to Potentially Agnostic Biomarker
10.21037/tlcr-23-174 · 2023 · External reference
K‐Ras(G12C) Inhibitors Allosterically Control GTP Affinity and Effector Interactions
10.1038/nature12796 · 2013 · External reference
A RhoA Structure with Switch II Flipped Outward Revealed the Conformational Dynamics of Switch II Region
10.1016/j.jsb.2023.107942 · 2023 · External reference
Inhibition Mechanism of MRTX1133 on KRASG12D: a Molecular Dynamics Simulation and Markov state Model Study
10.1007/s10822-023-00498-1 · 2023 · External reference
GEF‐Mediated GDP/GTP Exchange by Monomeric GTPases: a Regulatory Role for Mg2+?
10.1002/(sici)1521-1878(199806)20:6<516::aid-bies11>3.0.co;2-3 · 1998 · External reference
Targeting KRAS Mutant Cancers with a Covalent G12C‐Specific Inhibitor
10.1016/j.cell.2018.01.006 · 2018 · External reference
FDA Approves First KRAS Inhibitor: Sotorasib
10.1158/2159-8290.cd-nb2021-0362 · 2021 · External reference
Adagrasib: First Approval
10.1007/s40265-023-01839-y · 2023 · External reference
Characteristics and Treatment Outcomes in Advanced‐Stage Non‐Small Cell Lung Cancer Patients with a KRAS G12C Mutation: a Real‐World Study
10.3390/jcm11144098 · 2022 · External reference
Targeted Therapies for KRAS‐Mutant Non‐Small Cell Lung Cancer: from Preclinical Studies to Clinical Development—A Narrative Review
10.21037/tlcr-22-639 · 2023 · External reference
Molecular Profile of KRAS G12C‐Mutant Colorectal and Non‐Small‐Cell Lung Cancer
10.1186/s12885-021-07884-8 · 2021 · External reference
Recent Progress in Targeted Therapy for Non‐Small Cell Lung Cancer
10.3389/fphar.2023.1125547 · 2023 · External reference
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
10.1056/nejmoa1917239 · 2020 · External reference
KRAS G12C Mutations in NSCLC: From Target to Resistance
10.3390/cancers13112541 · 2021 · External reference
Long‐Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C‐Mutated Non–Small‐Cell Lung Cancer: 2‐Year Analysis of CodeBreaK 100
10.1200/jco.22.02524 · 2023 · External reference
Safety Assessment of KRAS (G12C) Inhibitors Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real‐World Pharmacovigilance Study
10.1016/j.lungcan.2024.107966 · 2024 · External reference
Sotorasib versus docetaxel for Previously Treated Non‐Small‐Cell Lung Cancer with KRASG12C Mutation: A Randomised, Open‐Label, Phase 3 Trial
10.1016/s0140-6736(23)00221-0 · 2023 · External reference
Sotorasib in KRASG12C Mutated Lung Cancer: Can We Rule out Cracking KRAS Led to Worse Overall Survival?
10.1016/j.tranon.2022.101591 · 2023 · External reference
Adagrasib in Non–Small‐Cell Lung Cancer Harboring a KRAS G12C Mutation
10.1056/nejmoa2204619 · 2022 · External reference
Intracranial Efficacy of Adagrasib in Patients from the KRYSTAL‐1 Trial with KRASG12C‐Mutated Non–Small‐Cell Lung Cancer Who Have Untreated CNS Metastases
10.1200/jco.23.00046 · 2023 · External reference
Adagrasib versus Docetaxel in KRASG12C‐Mutated Non‐Small‐Cell Lung Cancer (KRYSTAL‐12): A Randomised, Open‐label, Phase 3 Trial
10.1016/s0140-6736(25)00866-9 · 2025 · External reference
Acquired Resistance to KRAS G12C Inhibition in Cancer
10.1056/nejmoa2105281 · 2021 · External reference
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights from in Vitro Experiments
10.1016/j.jtho.2021.04.015 · 2021 · External reference
The next‐Generation KRAS Inhibitors…What Comes after sotorasib and adagrasib?
10.1016/j.lungcan.2024.107886 · 2024 · External reference
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
10.1158/2159-8290.cd-22-0158 · 2022 · External reference
Phase I Study of JNJ‐74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation
10.1093/oncolo/oyab080 · 2022 · External reference
Single‐Agent Divarasib (GDC‐6036) in Solid Tumors with a KRAS G12C Mutation
10.1056/nejmoa2303810 · 2023 · External reference
Discovery and Characterization of Divarasib (GDC‐6036), a Potent Covalent Inhibitor of KRAS G12C
10.1021/acs.jmedchem.5c02272 · 2026 · External reference
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
10.1200/jco.23.00434 · 2023 · External reference
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients with Advanced NSCLC: Results from a Phase 2 Pivotal Study
10.1016/j.jtho.2024.08.005 · 2024 · External reference
Pan‐Tumor Activity of Olomorasib, A Next‐Generation KRAS G12C Inhibitor in KRAS G12C‐Mutant Advanced Solid Tumors: A First‐in‐Human Study
10.1038/s41467-026-69943-7 · 2026 · External reference
Glecirasib plus Sitneprotafib in Patients with KRASG12C‐Mautated Non‐Small‐Cell Lung Cancer in China: An Open‐Label, Multicentre, Single‐Arm, Phase 1/2a Trial
10.1016/s2213-2600(25)00258-9 · 2026 · External reference
Combining RAS(ON) G12C‐Selective Inhibitor with SHP2 Inhibition Sensitises Lung Tumours to Immune Checkpoint Blockade
10.1038/s41467-024-52324-3 · 2024 · External reference
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer
10.1200/jco-24-02026 · 2025 · External reference
Sotorasib with Panitumumab in Chemotherapy‐Refractory KRASG12C‐Mutated Colorectal Cancer: A Phase 1b Trial
10.1038/s41591-023-02717-6 · 2024 · External reference
Adagrasib With or Without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
10.1056/nejmoa2212419 · 2023 · External reference
Glecirasib With or Without Cetuximab in Previously Treated Locally Advanced or Metastatic Colorectal Cancer with KRASG12C Mutation (JAB‐21822‐1002 and JAB‐21822‐1007): Two Open‐Label, Non‐Randomised Phase 1/2 Trials
10.1016/s2468-1253(25)00267-5 · 2026 · External reference
Divarasib Plus Cetuximab in KRAS G12C‐Positive Colorectal Cancer: A Phase 1b Trial
10.1038/s41591-023-02696-8 · 2024 · External reference
Fulzerasib plus Cetuximab in First‐Line KRASG12C‐Mutated Non‐Small‐Cell Lung Cancer (KROCUS): A Single‐Arm, Multicentre, Phase 1b/2 Trial
10.1016/s1470-2045(25)00764-8 · 2026 · External reference
D3S‐001 in Advanced Solid Tumors with KRASG12C Mutations: A Phase 1 Trial
10.1038/s41591-025-03688-6 · 2025 · External reference
First Results of Migoprotafib, A Potent and Highly Selective Src Homology‐2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
10.1158/1535-7163.mct-24-0466 · 2025 · External reference
JAB‐3312, A Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD‐1 Blockade Therapies
10.1158/1078-0432.ccr-24-3691 · 2025 · External reference
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
10.1158/1535-7163.mct-23-0870 · 2024 · External reference
Small‐Molecule Inhibition of MAP2K4 Is Synergistic With RAS Inhibitors in KRAS‐Mutant Cancers
10.1073/pnas.2319492121 · 2024 · External reference
Ifebemtinib plus Garsorasib as First‐Line Treatment for KRASG12C‐Mutated Non‐Small‐Cell Lung Cancer in China: A Multicentre, Single‐Arm Expansion Cohort From a Phase 1b/2 Trial
10.1016/s2213-2600(26)00142-6 · 2026 · External reference
Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C‐Mutant Advanced NSCLC
10.1016/j.jtho.2025.11.018 · 2026 · External reference
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
10.1021/acs.jmedchem.6b00680 · 2016 · External reference
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
10.1158/1078-0432.ccr-18-0368 · 2019 · External reference
Identification of GDC‐1971 (RLY‐1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors
10.1021/acs.jmedchem.3c00483 · 2023 · External reference
Design and Discovery of MRTX0902, a Potent, Selective, Brain‐Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction
10.1021/acs.jmedchem.2c00741 · 2022 · External reference
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
10.1021/acs.jmedchem.0c01170 · 2020 · External reference
Rapid Non‐Uniform Adaptation to Conformation‐Specific KRAS(G12C) Inhibition
10.1038/s41586-019-1884-x · 2020 · External reference
The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with KRAS Mutation‐Positive Solid Tumors
10.1158/1078-0432.ccr-25-3725 · 2026 · External reference
Acquired Resistance to KRAS G12C Small‐Molecule Inhibitors via Genetic/Nongenetic Mechanisms in Lung Cancer
10.1126/sciadv.ade3816 · 2023 · External reference
Adeno‐to‐Squamous Transition Drives Resistance to KRAS Inhibition in LKB1 Mutant Lung Cancer
10.1016/j.ccell.2024.01.012 · 2024 · External reference
KRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population‐Based Demographics and Survival Data from the National Swedish Lung Cancer Registry
10.1016/j.cllc.2023.05.002 · 2023 · External reference
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C‐Mutant Non–Small Cell Lung Cancer
10.1158/1078-0432.ccr-22-0383 · 2022 · External reference
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
10.1056/nejmoa2308795 · 2023 · External reference
Hepatotoxicity in Patients with Non‐Small Cell Lung Cancer Treated with sotorasib after Prior Immunotherapy: A Comprehensive Clinical and Pharmacokinetic Analysis
10.1016/j.ebiom.2024.105074 · 2024 · External reference
Second‐Generation Atroposelective Synthesis of KRAS G12C Covalent Inhibitor GDC‐6036
10.1021/acs.orglett.3c00961 · 2023 · External reference
A Pan‐KRAS Inhibitor and Its Derived Degrader Elicit Multifaceted Anti‐Tumor Efficacy in KRAS‐Driven Cancers
10.1016/j.ccell.2025.07.006 · 2025 · External reference
Daraxonrasib in Previously Treated Advanced RAS‐Mutated Pancreatic Cancer
10.1056/nejmoa2505783 · 2026 · External reference
Daraxonrasib for Previously Treated RAS ‐Mutant Non–Small‐Cell Lung Cancer
10.1056/nejmoa2504059 · 2026 · External reference
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
10.1056/nejmoa2605555 · 2026 · External reference
A First‐in‐Class EGFR‐Directed KRAS G12V Selective Inhibitor
10.1016/j.ccell.2025.05.016 · 2025 · External reference
A Phase II Trial of an Extended‐Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer
10.1158/1078-0432.ccr-25-3189 · 2026 · External reference
Coinhibition of the MEK/RTK Pathway Has High Therapeutic Efficacy in KRAS‐Mutant Non‐Small Cell Lung Cancer
10.1038/s41392-025-02382-w · 2025 · External reference
The Paradox‐Breaking panRAF plus SRC family Kinase Inhibitor, CCT3833, Is Effective in Mutant KRAS‐Driven Cancers
10.1016/j.annonc.2020.10.483 · 2021 · External reference
Anti‐Tumor Efficacy of a Potent and Selective Non‐Covalent KRASG12D Inhibitor
10.1038/s41591-022-02007-7 · 2022 · External reference
Tumour‐Selective Activity of RAS‐GTP Inhibition in Pancreatic Cancer
10.1038/s41586-024-07379-z · 2024 · External reference
Remodeling the Immunosuppressive Microenvironment of KARS‐LKB1 co‐Mutant Non‐Small Cell Lung Cancer via Targeted PGAM5 siRNA Delivery for Enhanced Immunotherapy
10.1016/j.mattod.2026.01.001 · 2026 · External reference
Toward Personalized Treatment Approaches for Non‐Small‐Cell Lung Cancer
10.1038/s41591-021-01450-2 · 2021 · External reference
A Single‐Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients with Advanced Nonsquamous NSCLC with KRAS G12C Mutation (WJOG14821L, SCARLET)
10.1016/j.jtho.2025.01.006 · 2025 · External reference
AMG‐510 and Cisplatin Combination Increases Antitumor Effect in Lung Adenocarcinoma with Mutation of KRAS G12C: A Preclinical and Translational Research
10.1007/s12672-023-00698-z · 2023 · External reference
Targeted Degradation of Oncogenic KRAS G12C by VHL‐Recruiting PROTACs
10.1021/acscentsci.0c00411 · 2020 · External reference
Small‐Molecule PROTACs: Novel Agents for Cancer Therapy
10.4155/fmc-2019-0340 · 2020 · External reference
Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy
10.1146/annurev-cancerbio-061521-082114 · 2023 · External reference
Generation of Actionable, Cancer‐Specific Neoantigens from KRAS(G12C) with adagrasib
10.1073/pnas.2509012122 · 2025 · External reference
T Cell Receptor Gene Therapy Targeting KRAS G12V for Advanced Pancreatic Cancer in a Single‐Arm Phase 1/2 Clinical Trial
10.1016/j.ymthe.2026.03.012 · 2026 · External reference
Neoantigen T‐Cell Receptor Gene Therapy in Pancreatic Cancer
10.1056/nejmoa2119662 · 2022 · External reference
KRAS Mutant Colorectal Tumors
10.4161/sgtp.18751 · 2012 · External reference
K‐Ras Mutations and Benefit from cetuximab in Advanced Colorectal Cancer
10.1056/nejmoa0804385 · 2008 · External reference
KRAS p.G12C Mutated‐Targeted Treatments in Metastatic Colorectal Cancer: a Systematic Review and Meta‐Analysis
2026 · External reference
Targeting KRAS in Colorectal Cancer: a Bench to Bedside Review
10.3390/ijms241512030 · 2023 · External reference
Association of KRAS G12C Status with Age at Onset of Metastatic Colorectal Cancer
10.3390/cimb46020088 · 2024 · External reference
A Narrative Review of RAS Mutations in Early‐Stage Colorectal Cancer: Mechanisms and Clinical Implications
10.3390/medicina61030408 · 2025 · External reference
A Neomorphic Protein Interface Catalyzes Covalent Inhibition of RAS G12D Aspartic Acid in Tumors
10.1126/science.ads0239 · 2025 · External reference
Biochemical and Structural Analysis of Common Cancer‐Associated KRAS Mutations
10.1158/1541-7786.mcr-15-0203 · 2015 · External reference
Expanding the Reach of Precision Oncology by Drugging all KRAS Mutants
10.1158/2159-8290.cd-21-1331 · 2022 · External reference
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
10.3390/cancers16020412 · 2024 · External reference
Assessment of KRASG12C Inhibitors for Colorectal Cancer
10.3389/fonc.2024.1412435 · 2024 · External reference
Feedback Activation of EGFR/Wild‐Type RAS Signaling Axis Limits KRASG12D Inhibitor Efficacy in KRASG12D‐Mutated Colorectal Cancer
10.1038/s41388-023-02676-9 · 2023 · External reference
Efficacy of Dual KRASG12D–EGFR Blockade versus Triple Combinations in Patient‐Derived Models of KRASG12D‐Mutant Colorectal Cancer
10.1038/s41419-026-08900-0 · 2026 · External reference
Anti‐Tumor Efficacy of HRS‐4642 and Its Potential Combination with Proteasome Inhibition in KRAS G12D‐Mutant Cancer
10.1016/j.ccell.2024.06.001 · 2024 · External reference
KRAS‐G12D Inhibitor HRS‐4642 plus Chemotherapy in Advanced KRASG12D‐Mutant Pancreatic Cancer: a Phase 1b/2 Trial
10.1038/s41591-026-04538-9 · 2026 · External reference
Setidegrasib in Advanced Non–Small‐Cell Lung Cancer and Pancreatic Cancer
10.1056/nejmoa2600752 · 2026 · External reference
Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS G12D Inhibitor, in Colorectal Cancer Treatment
10.21873/anticanres.16629 · 2023 · External reference
Emerging Therapeutic Strategies for Non‐G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V
10.1007/s12029-026-01579-8 · 2026 · External reference
Isoform‐Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D
10.1016/j.celrep.2019.07.026 · 2019 · External reference
Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
10.1371/journal.pone.0055793 · 2013 · External reference
A Comparative Analysis of Individual RAS Mutations in Cancer Biology
10.3389/fonc.2019.01088 · 2019 · External reference
Anti‐EGFR and Anti‐VEGF Agents: Important Targeted Therapies of Colorectal Liver Metastases
10.3748/wjg.v20.i15.4263 · 2014 · External reference
Association of KRAS G13D Tumor Mutations with Outcome in Patients with Metastatic Colorectal Cancer Treated with First‐Line Chemotherapy with or without Cetuximab
10.1200/jco.2012.42.2592 · 2012 · External reference
Mechanisms of Resistance to Anti‐EGFR Therapy in Colorectal Cancer
10.18632/oncotarget.14012 · 2017 · External reference
KRAS G13D Sensitivity to Neurofibromin‐Mediated GTP Hydrolysis
10.1073/pnas.1908353116 · 2019 · External reference
Novel Druggable Space in human KRAS G13D Discovered Using Structural Bioinformatics and a P‐Loop Targeting Monoclonal Antibody
10.1038/s41598-024-70217-9 · 2024 · External reference
Frequency and Type of KRAS Mutations in Routine Diagnostic Analysis of Metastatic Colorectal Cancer
10.1016/j.prp.2009.07.010 · 2009 · External reference
Evaluation of KRAS and NRAS Mutations in Metastatic Colorectal Cancer: an 8‐Year Study of 10 754 Patients in Turkey
10.1002/1878-0261.70042 · 2025 · External reference
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
10.1093/jnci/djr523 · 2012 · External reference
BRAF and NRAS Locus‐Specific Variants Have Different Outcomes on Survival to Colorectal Cancer
10.1158/1078-0432.ccr-16-1541 · 2017 · External reference
Focus on RAS Codon 61 Mutations in Metastatic Colorectal Cancer: a Retrospective Analysis
10.3390/cancers16050988 · 2024 · External reference
Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations
10.1158/1078-0432.ccr-17-0400 · 2017 · External reference
Targeting the SHOC2–RAS Interaction in RAS‐Mutant Cancers
10.1038/s41586-025-08931-1 · 2025 · External reference
Mutant KRAS Modulates Colorectal Cancer Cells Invasive Response to Fibroblast‐Secreted Factors through the HGF / C‐MET Axis
10.1002/ijc.34225 · 2022 · External reference
Deciphering Treatment Resistance in Metastatic Colorectal Cancer: Roles of Drug Transports, EGFR Mutations, and HGF/c‐MET Signaling
10.3389/fphar.2023.1340401 · 2023 · External reference
Intratumoral Heterogeneity and Drug Resistance in Cancer
10.1186/s12935-025-03734-w · 2025 · External reference
Gut Microbiota Composition in Chemotherapy and Targeted Therapy of Patients with Metastatic Colorectal Cancer
10.3389/fonc.2022.955313 · 2022 · External reference
Microbial Metabolites in Colorectal Tumorigenesis and Cancer Therapy
10.1080/19490976.2023.2203968 · 2023 · External reference
Metabolic Interactions: How Gut Microbial Metabolites Influence Colorectal Cancer
10.3389/fmicb.2025.1611698 · 2025 · External reference
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: the Long Road to Cure
10.3390/cancers15205015 · 2023 · External reference
The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma
10.3390/jcm13072103 · 2024 · External reference
Treatment of KRAS‐Mutated Pancreatic Cancer: New Hope for the Patients?
10.3390/cancers17152453 · 2025 · External reference
Prognostic Role of Specific KRAS Mutations Detected in Aspiration and Liquid Biopsies from Patients with Pancreatic Cancer
10.3390/genes15101302 · 2024 · External reference
Evaluation of KRAS Inhibitor‐Directed Therapies for Pancreatic Cancer Treatment
10.3389/fonc.2024.1402128 · 2024 · External reference
KRAS G12D Targeted Therapies for Pancreatic Cancer: Has the Fortress Been Conquered?
10.3389/fonc.2022.1013902 · 2022 · External reference
Pancreatic Cancer in 2025: Have We Found a Solution?
10.3748/wjg.v31.i43.111433 · 2025 · External reference
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
10.1158/1078-0432.ccr-23-2098 · 2024 · External reference
KRASG12D inhibition Reprograms the Microenvironment of Early and Advanced Pancreatic Cancer to Promote FAS‐Mediated Killing by CD8+ T Cells
10.1016/j.ccell.2023.07.002 · 2023 · External reference
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer
10.1158/0008-5472.can-23-2504 · 2024 · External reference
Targeted Therapies in Pancreatic Cancer: a New Era of Precision Medicine
10.3390/biomedicines12102175 · 2024 · External reference
KRAS: the Achilles' heel of Pancreas Cancer Biology
10.1172/jci191939 · 2025 · External reference
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
10.3390/curroncol31040150 · 2024 · External reference
A Stumbling Block in Pancreatic Cancer Treatment: Drug Resistance Signaling Networks
10.3389/fcell.2024.1462808 · 2025 · External reference
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
10.1158/2159-8290.cd-19-1006 · 2020 · External reference
Translational and Therapeutic Evaluation of RAS‐GTP Inhibition by RMC‐6236 in RAS‐Driven Cancers
10.1158/2159-8290.cd-24-0027 · 2024 · External reference
PROTAC: a Revolutionary Technology Propelling Small Molecule Drugs into the next Golden Age
10.3389/fonc.2025.1676414 · 2025 · External reference
Recent Advances in Targeting the “Undruggable” Proteins: From Drug Discovery to Clinical Trials
10.1038/s41392-023-01589-z · 2023 · External reference
Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions
10.3390/curroncol31090385 · 2024 · External reference
Clinicogenomic Landscape of Pancreatic Adenocarcinoma Identifies KRAS Mutant Dosage as Prognostic of Overall Survival
10.1038/s41591-024-03362-3 · 2025 · External reference
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS‐Mutant Cancers in Mouse Models and Patients
10.1158/2159-8290.cd-19-1167 · 2020 · External reference
Functional Analysis of Rare RAS Variants of Unknown Significance
10.1158/2767-9764.crc-25-0188 · 2025 · External reference
The Rapidly Growing Landscape of RAS Inhibitors: from Selective Allele Blockade to Broad Inhibition Strategies
10.1002/1878-0261.70149 · 2025 · External reference
Pancreatic Cancer: Advances and Challenges
10.1016/j.cell.2023.02.014 · 2023 · External reference
Targeting KRAS in Cancer
10.1038/s41591-024-02903-0 · 2024 · External reference
Uridine‐Derived Ribose Fuels Glucose‐Restricted Pancreatic Cancer
10.1038/s41586-023-06073-w · 2023 · External reference
Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy
10.1038/nm.4123 · 2016 · External reference
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified through Broad‐Based Tumor Genotyping
10.1634/theoncologist.2011-0386 · 2012 · External reference
Cholangiocarcinoma: What Are the Options in all Comers and How Has the Advent of Molecular Profiling Opened the Way to Personalised Medicine ?
10.1016/j.ejca.2022.11.006 · 2023 · External reference
High‐Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated
10.1371/journal.pone.0052795 · 2012 · External reference
The Current state of the Art and Future Trends in RAS‐Targeted Cancer Therapies
10.1038/s41571-022-00671-9 · 2022 · External reference
PIK3CA and KRAS Mutations Predict for Response to everolimus Therapy: Now That's RAD001
10.1172/jci44026 · 2010 · External reference
KRAS Mutated Colorectal Cancers with or without PIK3CA Mutations: Clinical and Molecular Profiles Inform Current and Future Therapeutics
10.1016/j.critrevonc.2023.103987 · 2023 · External reference
Dual Inhibition of GTP‐Bound KRAS and mTOR in Lung Adenocarcinoma and Squamous Cell Carcinoma Harboring KRAS G12C
10.1186/s12964-025-02187-y · 2025 · External reference
Utility of Molecular Subtypes and Genetic Alterations for Evaluating Clinical Outcomes in 1029 Patients with Endometrial Cancer
10.1038/s41416-023-02203-3 · 2023 · External reference
Contemporary Fertility‐Sparing Management Options of Early Stage Endometrioid Endometrial Cancer in Young Nulliparous Patients
10.3390/jcm11010196 · 2021 · External reference
KRAS Status Is Related to Histological Phenotype in Gastric Cancer: Results from a Large Multicentre Study
10.1007/s10120-019-00972-6 · 2019 · External reference
Systemic Therapy of Gastric Cancer—State of the Art and Future Perspectives
10.3390/cancers16193337 · 2024 · External reference
Comprehensive Pan‐Cancer Genomic Landscape of KRAS Altered Cancers and Real‐World Outcomes in Solid Tumors
10.1038/s41698-022-00334-z · 2022 · External reference
KRAS Mutation in Rare Tumors: a Landscape Analysis of 3453 Chinese Patients
10.3389/fmolb.2022.831382 · 2022 · External reference
RAS‐Targeted Cancer Therapy: Advances in Drugging Specific Mutations
2020 · External reference
Therapeutic Targets of KRAS in Colorectal Cancer
10.3390/cancers13246233 · 2021 · External reference
Metabolic Plasticity in Pancreatic Ductal Adenocarcinoma Progression and Response to Treatment
10.1186/s12943-026-02620-x · 2026 · External reference
CDK8 remodels the Tumor Microenvironment and Promotes Resistance to KRASG12D Inhibitors and Daraxonrasib in PDAC
10.1038/s44318-026-00854-5 · 2026 · External reference
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
10.1158/2159-8290.cd-20-0187 · 2020 · External reference
KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges
10.3390/cancers17172803 · 2025 · External reference
STK11/LKB1 Mutations and PD‐1 Inhibitor Resistance in KRAS‐Mutant Lung Adenocarcinoma
10.1158/2159-8290.cd-18-0099 · 2018 · External reference
Impact of Co‐Mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL‐1 Trial
10.1158/1078-0432.ccr-24-2310 · 2025 · External reference
Concurrent Genetic and Non‐Genetic Resistance Mechanisms to KRAS Inhibition in Colorectal Cancer
10.1016/j.ccell.2026.04.009 · 2026 · External reference
Pan‐KRAS Inhibitor Disables Oncogenic Signalling and Tumour Growth
10.1038/s41586-023-06123-3 · 2023 · External reference
KRAS‐Targeted Therapies in Cancer: Novel Approaches and Overcoming Resistance
10.1136/bmjonc-2025-000946 · 2025 · External reference
Flourishing Innovation in KRAS Targeting: Recent Advances in Medicinal Chemistry Strategies and Future Perspectives
10.1016/j.bioorg.2025.109345 · 2026 · External reference
D3S‐001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
10.1158/2159-8290.cd-24-0006 · 2024 · External reference
Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor
10.1158/2159-8290.cd-25-1346 · 2026 · External reference
Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition
10.1158/1078-0432.ccr-25-1788 · 2026 · External reference
Targeting KRAS Mutations in Pancreatic Cancer: Opportunities for Future Strategies
10.3389/fmed.2024.1369136 · 2024 · External reference
Adaptive Feedback Signaling through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance
10.1016/j.jtho.2026.103991 · 2026 · External reference
Discovery of KRAS(G12D) Selective Degrader ASP3082
10.1038/s42004-025-01662-4 · 2025 · External reference
Sacituzumab Govitecan versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: the Randomized, Open‐Label Phase III EVOKE‐01 Study
10.1200/jco.24.00733 · 2024 · External reference
Datopotamab Deruxtecan versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: the Randomized, Open‐Label Phase III TROPION‐Lung01 Study
10.1200/jco-24-01544 · 2025 · External reference
Trastuzumab Deruxtecan in HER2 ‐Mutant Non–Small‐Cell Lung Cancer
10.1056/nejmoa2112431 · 2022 · External reference
Patritumab Deruxtecan (HER3‐DXd) in Patients with Active Brain Metastases of Non‐Small‐Cell Lung Cancer (TUXEDO‐3): A Multicentre, Single‐Arm, Phase 2 Trial
10.1016/s1470-2045(25)00465-6 · 2025 · External reference
Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights from the EVOKE‐01 Study
10.1158/2767-9764.crc-26-0070 · 2026 · External reference
